Merck

Evaxion Biotech is a clinical-stage company leveraging AI-immunology™ technology to decode the human immune system, developing novel immunotherapies for cancer and infectious diseases. Its pipeline includes three patient-specific cancer therapies in Phase I/IIa trials and vaccines targeting bacterial and viral infections.

Personalis, Inc. is a cancer genomics company based in Menlo Park, California, that specializes in genomic sequencing and data analysis services aimed at advancing personalized cancer therapies. Established in 2011, the company offers a range of products, including the NeXT Platform, which provides critical data for the development of personalized therapies, therapy selection, and diagnostics. Additionally, Personalis provides a liquid biopsy assay that examines various human genes to enhance cancer treatment strategies. The company's services support biopharmaceutical clients, universities, non-profit organizations, diagnostics companies, and government agencies, facilitating the creation of safer and more effective precision cancer therapies and immunotherapies. Personalis is recognized for its integration of sequencing technology and data interpretation, contributing to a comprehensive understanding of tumor biology and its interaction with the immune system.

N-Power Medicine is a biotechnology company focused on advancing drug development and clinical research, particularly within the field of oncology. The company operates a network of community oncology centers staffed with qualified professionals who assist in identifying suitable patients for research studies. This approach not only accelerates the pace of clinical trials but also aims to enhance the diversity of patient populations involved in these studies. By facilitating faster and more efficient research processes, N-Power Medicine aims to support pharmaceutical companies and researchers in their efforts to innovate and improve cancer treatment options.

Evaxion Biotech is a clinical-stage company leveraging AI-immunology™ technology to decode the human immune system, developing novel immunotherapies for cancer and infectious diseases. Its pipeline includes three patient-specific cancer therapies in Phase I/IIa trials and vaccines targeting bacterial and viral infections.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Unnatural Products Inc. is a biotechnology company based in Santa Cruz, California, focused on drug discovery through innovative technology. Founded in 2016, the company specializes in designing and developing a platform that utilizes artificial intelligence and computational biology techniques to create macrocyclic peptides. These peptides target intracellular protein interactions, addressing drug targets that are typically considered undruggable. By harnessing machine learning to optimize chemical synthesis, Unnatural Products aims to accelerate the drug discovery process, offering potential therapeutic strategies for a wide range of medical conditions. Through its unique approach, the company seeks to pioneer new treatments where traditional methods have fallen short.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

IndyGeneUS AI is a genomics company specializing in creating the world's largest digital blockchain-encrypted repository of indigenous and diasporic African clinical and genomic data. The company uses proprietary technology to detect novel signature sequences, biomarkers, and polygenic risk scores by integrating multi-omics data, electronic healthcare records, and textual information.

Turbine Ltd, established in 2015 and headquartered in Budapest, Hungary, specializes in computational biology for cancer drug development. The company's core product is a predictive model that simulates cellular behavior, aiding in the discovery, preclinical testing, and development of cancer therapies. Turbine's platform leverages proprietary Simulated Cell technology and artificial intelligence to identify novel protein targets and precision biomarkers, ultimately enhancing the translation of research into effective patient treatments.

Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

PreciseDx is a specialized company focused on cancer risk stratification, providing patient-specific risk assessments through the analysis of morphological features. By leveraging artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that enhance the understanding of a patient's risk profile and potential outcomes. This innovative approach allows clinical teams to gain valuable insights and actionable intelligence, facilitating more personalized treatment decisions. The company's expertise spans clinical modeling, patient phenotyping, image analysis, and the application of big data in real-world scenarios, ultimately aiming to improve patient outcomes and quality of life in cancer care and other diseases.

Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

M2Gen, Corp. is a health informatics solutions company headquartered in Tampa, Florida, established in 2006 at the Moffitt Cancer Center. It specializes in advancing precision medicine through its integrated clinical and molecular data platform, which analyzes data to enhance patient care. M2Gen provides evidence-based solutions that help identify disease susceptibility, predict drug responses, and match patients with optimal therapies. The company operates the Total Cancer Care Protocol, a comprehensive approach that studies patients throughout their lifetime, and collaborates with leading cancer centers through the Oncology Research Information Exchange Network (ORIEN). Additionally, M2Gen offers the M2Gen Portfolio, which supports biopharmaceutical companies in discovering new targets and biomarkers, improving clinical trial design and enrollment, and facilitating long-term post-market analysis. M2Gen was formerly known as Moffitt Genetics Corporation, Inc. and rebranded in August 2017. It operates as a subsidiary of the H. Lee Moffitt Cancer Center & Research Institute.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

OncoImmune is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for cancer and autoimmune diseases. Its pipeline includes CD24Fc, a fusion protein for preventing acute graft-versus-host disease, and ONC-392, a monoclonal antibody designed to reduce immune-related toxicities.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Seagen is a clinical-stage biotechnology company based in Bothell, Washington, that specializes in developing and commercializing monoclonal antibody-based therapies for cancer and autoimmune diseases. Founded in 1997, the company focuses on creating innovative cancer therapies, particularly antibody-drug conjugates, to treat various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, and breast cancer. Its lead product, SGN-35, is undergoing pivotal trials for relapsed or refractory Hodgkin lymphoma. In addition to SGN-35, Seagen is advancing several other product candidates through various stages of clinical trials, including SGN-40, SGN-33, SGN-70, and SGN-75. The company has established collaborations with several prominent pharmaceutical firms, enhancing its research capabilities and drug development efforts. Through its commitment to innovative cancer therapies, Seagen aims to improve treatment outcomes for patients with diverse types of cancer.

Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).

Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

ArQule, Inc. is a clinical-stage biopharmaceutical company focused on the research and development of targeted therapeutics for cancer and rare diseases. Founded in 1993 and headquartered in Burlington, Massachusetts, the company employs its ArQule Kinase Inhibitor Platform to design and develop novel small molecule drugs. ArQule's pipeline includes several investigational therapies, such as ARQ 531, a dual inhibitor of Bruton’s tyrosine kinase for B-cell malignancies; miransertib, an AKT inhibitor for advanced endometrial cancer; and ARQ 75, also targeting AKT in solid tumors. Additionally, Derazantinib is a multi-kinase inhibitor in clinical trials for intrahepatic cholangiocarcinoma. The company has established license agreements with Basilea Pharmaceutica and Roivant Sciences for its therapeutic candidates. As of January 2020, ArQule operates as a subsidiary of Merck Sharp & Dohme Corp.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Navigating Cancer, Inc., established in 2008 and headquartered in Seattle, Washington, operates a Web-based patient care portal designed specifically for cancer programs. This platform enables cancer survivors to receive, organize, and understand their medical information, track their health, and engage with healthcare professionals. It also offers educational resources on various types of cancer and chemotherapy treatments. The portal aims to simplify practice workflows for healthcare providers, facilitate patient-centered care, and improve overall outcomes by empowering patients through technology.

Tilos Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative antibody therapeutics aimed at treating cancer, fibrosis, and related disorders. Founded in 2016 and based in Cambridge, Massachusetts, the company specializes in antibodies that target the Latency Associated Peptide of TGF beta, which plays a crucial role in regulating immune responses. Tilos Therapeutics is particularly focused on the modulation of regulatory T cells and effector cell regulation, leveraging the immune system to create effective therapies. By enhancing treatment options, Tilos aims to enable patients to begin their therapies more swiftly, ultimately leading to improved medical outcomes. As of mid-2019, Tilos operates as a subsidiary of Merck & Co., Inc.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for patients with cancer and other serious conditions. The company focuses on targeting HIF-2a, a transcription factor previously considered difficult to address with small molecules. Its lead drug candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma, and it is being evaluated in various settings, including in patients with von Hippel-Lindau disease-associated renal cell carcinoma and in combination with cabozantinib. Additionally, Peloton is advancing PT2567, another oral HIF-2a inhibitor in preclinical development for non-oncology indications such as pulmonary arterial hypertension. Founded in 2010 and previously known as Damascus Pharmaceutics, Peloton Therapeutics aims to leverage its scientific expertise and collaborations to become a leading biotech company in the region.

Navigating Cancer, Inc., established in 2008 and headquartered in Seattle, Washington, operates a Web-based patient care portal designed specifically for cancer programs. This platform enables cancer survivors to receive, organize, and understand their medical information, track their health, and engage with healthcare professionals. It also offers educational resources on various types of cancer and chemotherapy treatments. The portal aims to simplify practice workflows for healthcare providers, facilitate patient-centered care, and improve overall outcomes by empowering patients through technology.

TriNetX, Inc. operates a global health research network that facilitates clinical research and enhances the discovery of new therapies. The company provides a suite of tools, including TriNetX Live for analyzing patient populations, TriNetX Research for accessing longitudinal clinical data, and TriNetX Download for obtaining real-world clinical data through a unified platform. Additionally, TriNetX offers Attract Trials to streamline collaboration, Natural Language Processing to extract clinical information from physician notes, and specialized oncology solutions to link researchers with clinical and genomic data. Serving healthcare organizations, biopharmaceutical companies, and contract research organizations, TriNetX aims to optimize clinical trial design and recruitment, improving the speed and efficiency of bringing new therapies to market. Established in 2013, the company is headquartered in Cambridge, Massachusetts, with additional offices in Sydney, London, and Sao Paulo.

Clinithink Ltd is a UK-based healthcare software company that specializes in cloud-based data analytics solutions. Founded in 2009 and led by CEO Chris Tackaberry, Clinithink has developed innovative technologies, including its Clinical Language Indexing software (CLiX), which utilizes Natural Language Processing to transform unstructured clinical narratives into structured data. Its products, such as CLiX ENRICH, facilitate the collection and indexing of clinical trial data while allowing users to document information in their preferred narrative style. Additionally, Clinithink offers CLiX RARE, designed to assist in diagnosing genetic disorders in newborns. The company serves a diverse clientele, including healthcare providers, pharmaceutical companies, and content vendors, aiming to enhance data accessibility and improve decision-making within the healthcare sector.

Immune Design Corp., a clinical-stage immunotherapy company based in Seattle, Washington, focuses on enabling the body's immune system to combat diseases, with a primary emphasis on cancer treatment. The company leverages its ZVex and GLAAS discovery platforms to develop innovative therapies. Its lead product candidate is G100, currently in Phase II clinical trials for treating follicular non-Hodgkin lymphoma, both as a monotherapy and in combination therapy. Immune Design has collaboration and license agreements with Sanofi Pasteur. The company was founded in 2008 and operates under the umbrella of Merck & Co., Inc.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Sutro Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF platform. Its pipeline includes STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Pelago specializes in virtual substance use management, empowering members to overcome addiction, primarily tobacco, alcohol, or opioids. It offers cognitive behavioral therapy (CBT) and medication-assisted treatment (MAT) programs, delivered via an accessible platform that integrates with health plans and wellness platforms.

Viralytics Limited is a biotechnology company based in Sydney, Australia, specializing in the development and commercialization of oncolytic immunotherapies for cancer treatment. The company’s lead product, CAVATAK, is a proprietary formulation of a common cold virus that is currently undergoing Phase Ib and Phase II clinical trials for various cancers, including melanoma, lung, and bladder cancer. In addition to CAVATAK, Viralytics is developing EVATAK, aimed at treating ovarian, prostate, and gastric cancers. The company leverages the cancer-targeting properties of benign viruses to enhance the efficacy of cancer therapies while minimizing side effects. Formerly known as Psiron Ltd., Viralytics rebranded in December 2006 and has operations in Newcastle, Australia. As of June 2018, Viralytics is a subsidiary of Merck & Co. Inc.

Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at expanding global access to these treatments. The company leverages its expertise in antibody discovery, molecular design, and manufacturing processes to create innovative solutions that accelerate the development of biotherapeutics while significantly lowering manufacturing costs. Utilizing machine learning-driven technologies, Just Evotec Biologics provides clients with integrated designs that streamline the entire process from development to production, ensuring efficient and effective delivery of biologic therapies.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on developing innovative medicines for chronic pain management and neurogenic disorders. The company specializes in targeting P2X3 receptors found in nerve fibers, creating small molecule compounds designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy. Afferent's lead compound, AF-219, has successfully completed two Phase 1 clinical studies, positioning the company to advance its portfolio of therapeutics aimed at improving the quality of life for patients suffering from various pain-related ailments. Founded in 2009, Afferent Pharmaceuticals is dedicated to advancing the understanding and treatment of chronic pain through scientific innovation.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Founded in 2008, medCPU develops real-time enterprise decision support software for hospitals in the United States. Its core product, medCPU Advisor, integrates with electronic medical records to analyze both structured and unstructured data, generating precise prompts for clinical care consideration.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

WellDoc, Inc. is a healthcare technology company focused on chronic disease management, particularly diabetes. Founded in 2005 and headquartered in Baltimore, Maryland, with additional offices in Wilmington, Delaware, and Bengaluru, India, WellDoc develops innovative solutions that integrate into existing healthcare workflows. Its flagship platform, DiabetesManager, provides personalized, real-time coaching and support for patients and healthcare providers, facilitating self-management and adherence to treatment regimens. The platform features tools for medication reminders, alerts for out-of-range metrics, and cloud-based analytics for tracking health outcomes. Additionally, WellDoc offers BlueStar, a mobile prescription therapy solution that guides patients in managing their diabetes. The company serves various stakeholders in the healthcare ecosystem, including payors, employers, pharmaceutical companies, and medical device firms, and has established strategic partnerships to enhance its offerings.

Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at expanding global access to these treatments. The company leverages its expertise in antibody discovery, molecular design, and manufacturing processes to create innovative solutions that accelerate the development of biotherapeutics while significantly lowering manufacturing costs. Utilizing machine learning-driven technologies, Just Evotec Biologics provides clients with integrated designs that streamline the entire process from development to production, ensuring efficient and effective delivery of biologic therapies.

Navigating Cancer, Inc., established in 2008 and headquartered in Seattle, Washington, operates a Web-based patient care portal designed specifically for cancer programs. This platform enables cancer survivors to receive, organize, and understand their medical information, track their health, and engage with healthcare professionals. It also offers educational resources on various types of cancer and chemotherapy treatments. The portal aims to simplify practice workflows for healthcare providers, facilitate patient-centered care, and improve overall outcomes by empowering patients through technology.

cCAM Biotherapeutics Ltd. is a clinical-stage biotechnology company based in Misgav, Israel, focused on the discovery and development of innovative immunotherapies for cancer treatment. The company is developing CM-10, an immunomodulatory antibody designed to enhance the immune system's ability to target and attack tumors by binding to CEACAM1, a protein that cancer cells exploit to evade immune responses. cCAM's lead therapeutic candidate, CM-24, is a humanized anti-CEACAM1 monoclonal antibody aimed at treating advanced and recurrent cancers, including melanoma, non-small-cell lung cancer, bladder, gastric, colorectal, and ovarian cancers. Established in 2010, cCAM Biotherapeutics aims to provide effective treatment options for patients facing various malignancies.

Founded in 2008, medCPU develops real-time enterprise decision support software for hospitals in the United States. Its core product, medCPU Advisor, integrates with electronic medical records to analyze both structured and unstructured data, generating precise prompts for clinical care consideration.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Incorporated in 2007 and headquartered in South San Francisco, California, the company is engaged in creating novel treatments informed by key biological pathways. Its product candidates include Aldafermin, an engineered variant of the FGF19 hormone currently in Phase 2b clinical trials for non-alcoholic steatohepatitis (NASH), and NGM313, an agonistic antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates in development include NGM395 for metabolic syndrome, NGM120 to address cancer anorexia/cachexia syndrome, NGM217 aimed at improving insulin production in diabetes patients, and NGM621 to target a protein involved in age-related macular degeneration. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and development efforts in creating impactful medicines that enhance patient health.

Daktari Diagnostics, Inc. is a healthcare solutions company based in Cambridge, Massachusetts, focused on developing portable point-of-care diagnostic platforms to enhance disease management globally. Founded in 2008, the company offers several innovative products, including Daktari Virology for the detection of Hepatitis C and HIV, Daktari InSight, a cloud-based data management service, and Daktari Sickle Cell, which identifies infants with sickle cell disease from a single drop of blood. Daktari’s technology is designed specifically for resource-poor markets, featuring built-in wireless connectivity that facilitates real-time data sharing among healthcare providers. By delivering critical diagnostic information efficiently, Daktari aims to improve clinical outcomes and support global health initiatives. The company's commitment to affordability and quality ensures that its products are accessible to healthcare professionals and patients worldwide.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Founded in 1992, Cubist Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing pharmaceutical products that address unmet medical needs in acute care settings. Its primary product is CUBICIN, the first antibiotic in its class, used for treating serious infections. The company's pipeline includes drugs targeting Clostridium difficile-associated diarrhea, multi-drug resistant Gram-negative infections, and respiratory syncytial virus infections.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Cleveland HeartLab, Inc. is a specialty clinical laboratory dedicated to the prevention and management of cardiovascular disease (CVD). The company specializes in novel biomarker technologies and develops proprietary diagnostic tests aimed at improving the early identification of individuals at risk for CVD. Cleveland HeartLab offers a range of clinical laboratory services, including an inflammatory panel for CVD, advanced CVD risk profiles, and lipid panels. By focusing on innovative molecular biomarker technologies, the company seeks to enhance the management and reduction of inflammation, ultimately contributing to better cardiovascular health outcomes.

Idenix Pharmaceuticals is a biopharmaceutical company focused on discovering and developing drugs for the treatment of viral diseases, primarily targeting hepatitis C virus (HCV). With operations in the United States and Europe, the company's research efforts have led to significant advancements in HCV treatment, including the completion of a proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. Idenix has also initiated a phase IIa clinical trial to evaluate its lead drug candidate, IDX184, in combination with existing therapies. In addition to HCV, Idenix is developing products and candidates aimed at treating hepatitis B virus (HBV), human immunodeficiency virus type I (HIV), and acquired immune deficiency syndrome (AIDS).

Founded in 2008, medCPU develops real-time enterprise decision support software for hospitals in the United States. Its core product, medCPU Advisor, integrates with electronic medical records to analyze both structured and unstructured data, generating precise prompts for clinical care consideration.

AdvanDx, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in molecular diagnostic tests for identifying pathogens responsible for critical infections in hospitalized patients. Founded in 2002, the company focuses on enhancing the speed and accuracy of pathogen identification through innovative testing methods. Its product offerings include QuickFISH and PNA FISH tests, which allow for the direct identification of bacteria and yeast from positive blood cultures, as well as XpressFISH, a platform designed to detect resistance markers. Additionally, AdvanDx provides PNA Probes for ribosomal RNA sequences and various accessories to support its testing systems. The company's products are distributed through a network of sales representatives and partners across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. AdvanDx aims to improve patient outcomes by enabling healthcare providers to optimize antibiotic therapy while reducing unnecessary antibiotic use and hospital costs. As of July 2015, AdvanDx operates as a subsidiary of OpGen, Inc.

WellDoc, Inc. is a healthcare technology company focused on chronic disease management, particularly diabetes. Founded in 2005 and headquartered in Baltimore, Maryland, with additional offices in Wilmington, Delaware, and Bengaluru, India, WellDoc develops innovative solutions that integrate into existing healthcare workflows. Its flagship platform, DiabetesManager, provides personalized, real-time coaching and support for patients and healthcare providers, facilitating self-management and adherence to treatment regimens. The platform features tools for medication reminders, alerts for out-of-range metrics, and cloud-based analytics for tracking health outcomes. Additionally, WellDoc offers BlueStar, a mobile prescription therapy solution that guides patients in managing their diabetes. The company serves various stakeholders in the healthcare ecosystem, including payors, employers, pharmaceutical companies, and medical device firms, and has established strategic partnerships to enhance its offerings.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Humedica is a clinical intelligence company that specializes in health analytics, offering tools designed for hospitals, physicians, and life sciences organizations. The company transforms unconnected data from various sources into actionable insights, enabling healthcare providers to make informed decisions. One of its key products, Humedica MinedShare, serves as a platform for clinical, operational, and financial benchmarking across the continuum of care, facilitating improved performance and outcomes in the healthcare sector. Through its innovative solutions, Humedica aims to enhance the quality of care and operational efficiency within the healthcare industry.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Remedy Informatics accelerates translational medicine discoveries by providing configurable biomedical informatics products built on the Mosaic™ Platform. Its offerings include patient registries and medical research software, enabling life science and healthcare institutions to improve patient care.

Daktari Diagnostics, Inc. is a healthcare solutions company based in Cambridge, Massachusetts, focused on developing portable point-of-care diagnostic platforms to enhance disease management globally. Founded in 2008, the company offers several innovative products, including Daktari Virology for the detection of Hepatitis C and HIV, Daktari InSight, a cloud-based data management service, and Daktari Sickle Cell, which identifies infants with sickle cell disease from a single drop of blood. Daktari’s technology is designed specifically for resource-poor markets, featuring built-in wireless connectivity that facilitates real-time data sharing among healthcare providers. By delivering critical diagnostic information efficiently, Daktari aims to improve clinical outcomes and support global health initiatives. The company's commitment to affordability and quality ensures that its products are accessible to healthcare professionals and patients worldwide.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Inspire Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The advanced compounds in the clinical pipeline are denufosol tetrasodium for cystic fibrosis and Prolacria for dry eye, both of which are in Phase III development, and AzaSite for blepharitis, which is in Phase II development.

HTG Molecular Diagnostics is a commercial-stage life sciences company based in Tucson, Arizona, specializing in precision medicine through its innovative HTG EdgeSeq platform. Established in 1997, the company offers a suite of molecular-based technology solutions for gene expression profiling and the measurement of various RNA types, including miRNA and mRNA. The HTG EdgeSeq technology automates sample processing, allowing for the rapid and simultaneous profiling of hundreds to thousands of molecular targets using minimal biological material. HTG Molecular Diagnostics markets a range of products, including instruments, assay kits, and software, which work together to facilitate efficient molecular profiling. Its offerings include several specialized panels designed for oncology and immuno-oncology applications. The company serves a diverse clientele comprising biopharmaceutical firms, academic research institutions, and molecular testing laboratories, distributing its products directly in the United States and Europe, as well as through international distributors.

Vaximm is a biotechnology company dedicated to developing active immunotherapies, specifically vaccines, for cancer patients. Their primary focus is on targeting the tumor vasculature, which is crucial for tumor growth. The company's initial product candidate, VXM01, has demonstrated significant anti-tumor activity in various animal studies and was set to enter first human clinical trials in 2011. Vaximm's vaccines utilize oral T-cell activators based on modified attenuated bacteria, designed to target a broad range of cancer-related antigens, offering advanced treatment options for cancer patients.

HTG Molecular Diagnostics is a commercial-stage life sciences company based in Tucson, Arizona, specializing in precision medicine through its innovative HTG EdgeSeq platform. Established in 1997, the company offers a suite of molecular-based technology solutions for gene expression profiling and the measurement of various RNA types, including miRNA and mRNA. The HTG EdgeSeq technology automates sample processing, allowing for the rapid and simultaneous profiling of hundreds to thousands of molecular targets using minimal biological material. HTG Molecular Diagnostics markets a range of products, including instruments, assay kits, and software, which work together to facilitate efficient molecular profiling. Its offerings include several specialized panels designed for oncology and immuno-oncology applications. The company serves a diverse clientele comprising biopharmaceutical firms, academic research institutions, and molecular testing laboratories, distributing its products directly in the United States and Europe, as well as through international distributors.

PHT is a leading provider of electronic patient reported outcome (ePRO) solutions utilized in clinical trials globally. The company specializes in web-based direct data capture and management technologies that enhance data quality, facilitating more accurate and comprehensive information collection for biopharmaceutical and medical device companies. PHT's LogPad and StudyPad Systems streamline trial processes, while the robust StudyWorks online portal offers study sponsors, monitors, and sites real-time access to critical data. This enables faster decision-making and ultimately contributes to the success of clinical trials, making PHT an essential partner in the pharmaceutical and clinical research sectors.

HTG Molecular Diagnostics is a commercial-stage life sciences company based in Tucson, Arizona, specializing in precision medicine through its innovative HTG EdgeSeq platform. Established in 1997, the company offers a suite of molecular-based technology solutions for gene expression profiling and the measurement of various RNA types, including miRNA and mRNA. The HTG EdgeSeq technology automates sample processing, allowing for the rapid and simultaneous profiling of hundreds to thousands of molecular targets using minimal biological material. HTG Molecular Diagnostics markets a range of products, including instruments, assay kits, and software, which work together to facilitate efficient molecular profiling. Its offerings include several specialized panels designed for oncology and immuno-oncology applications. The company serves a diverse clientele comprising biopharmaceutical firms, academic research institutions, and molecular testing laboratories, distributing its products directly in the United States and Europe, as well as through international distributors.

Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, specializing in oncology and genetic disorders. Founded in 2005, the company develops and commercializes a diverse array of diagnostic products and services aimed at improving patient management. Its offerings include various AmplideX reagents for detecting genetic markers, as well as comprehensive cancer diagnostic kits, such as QUANTIDEX and Signature assays that target specific mutations and gene fusions. Asuragen employs its patented Armored RNA technology in its diagnostics portfolio, which encompasses genetic and oncology testing products alongside industry-leading controls. The company also provides GLP testing services and operates a cGMP manufacturing facility, ensuring a seamless process from discovery to commercialization. With a focus on enhancing treatment outcomes through precise data, Asuragen plays a critical role in the medical community's efforts to improve patient care in oncology and genetics.

Cytel specializes in providing statistical software and advanced analytics tailored for clinical trial design and execution. With over thirty years of experience, the company supports biotech and pharmaceutical firms in managing uncertainty and making evidence-based decisions. Cytel's offerings include industry-leading software, data-driven analytics, and strategic consulting, focusing on areas such as protocol development, regulatory support, and enrollment forecasting. By delivering real-world evidence and operational expertise, Cytel helps clients enhance efficiency and reduce costs in the life sciences development process.

PHT is a leading provider of electronic patient reported outcome (ePRO) solutions utilized in clinical trials globally. The company specializes in web-based direct data capture and management technologies that enhance data quality, facilitating more accurate and comprehensive information collection for biopharmaceutical and medical device companies. PHT's LogPad and StudyPad Systems streamline trial processes, while the robust StudyWorks online portal offers study sponsors, monitors, and sites real-time access to critical data. This enables faster decision-making and ultimately contributes to the success of clinical trials, making PHT an essential partner in the pharmaceutical and clinical research sectors.

Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system/ocular disorders. Its marketed products include ONPATTRO, a treatment for hereditary transthyretin-mediated amyloidosis, and GIVLAARI, which targets acute hepatic porphyria. Alnylam’s pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with notable partners like Sanofi Genzyme and Regeneron Pharmaceuticals, and it collaborates with Vir Biotechnology on RNAi therapeutics for coronavirus infections. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is at the forefront of transforming RNAi science into innovative medicines to improve patient outcomes.

PHT is a leading provider of electronic patient reported outcome (ePRO) solutions utilized in clinical trials globally. The company specializes in web-based direct data capture and management technologies that enhance data quality, facilitating more accurate and comprehensive information collection for biopharmaceutical and medical device companies. PHT's LogPad and StudyPad Systems streamline trial processes, while the robust StudyWorks online portal offers study sponsors, monitors, and sites real-time access to critical data. This enables faster decision-making and ultimately contributes to the success of clinical trials, making PHT an essential partner in the pharmaceutical and clinical research sectors.

Acurian provides solutions needed to recruit, enroll, and retain patients for clinical trials. The company offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions. Acurian was founded in 1998 and is based in Horsham, Pennsylvania.

Acurian provides solutions needed to recruit, enroll, and retain patients for clinical trials. The company offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions. Acurian was founded in 1998 and is based in Horsham, Pennsylvania.